Profound Medical Corp. Cash Flow Statement
PROF|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Profound Medical Corp. used $23M in operating cash flow and negative free cash flow of $24M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$27.8M | -$28.3M |
| Depreciation & Amortization | $707.0K | $727.0K |
| Operating Cash Flow | -$23.5M | -$22.6M |
| Capital Expenditures | $176.0K | - |
| Free Cash Flow | -$23.6M | - |
| FCF Margin | -221.3% | - |